文献速递鼻科

麦卢卡蜂蜜鼻窦冲洗治疗难治性慢性鼻窦炎的1期随机单盲安慰剂对照试验

Manuka honey sinus irrigations in recalcitrant chronic rhinosinusitis: phase 1 randomized, single-blinded, placebo-controlled trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-08-28

本研究为首次评估增强甲基乙二醛(MGO)的麦卢卡蜂蜜(MH)冲洗治疗难治性慢性鼻窦炎(CRS)安全性及初步疗效的1期随机单盲安慰剂对照试验。MH组安全性良好,无严重不良事件,嗅觉识别测试无变化,但细菌培养转阴率低于对照组。结论:每日两次16.5% MH+1.3 mg/mL MGO冲洗14天安全,但不优于培养导向口服抗生素联合生理盐水冲洗。

要点

  • 16.5%麦卢卡蜂蜜+1.3 mg/mL MGO鼻窦冲洗14天安全性良好。
  • MH组细菌培养减少率60%,对照组80%,MH未显示优效。
  • MH组仅1/10培养转阴,对照组7/15转阴。

核心结论

  • 每日两次16.5% MH联合1.3 mg/mL MGO鼻窦冲洗14天安全,但不优于培养导向口服抗生素联合每日两次生理盐水冲洗。

主要发现

  • MH组10例中6例(60%)细菌培养率降低,其中1例培养阴性;对照组15例中12例(80%)降低,其中7例培养阴性。
  • MH组无严重不良事件,UPSIT嗅觉识别测试无变化。

关键数值与推荐

  • MH组干预:14天每日两次16.5% MH+1.3 mg/mL MGO鼻窦冲洗,同时10天安慰剂片。
  • 对照组干预:14天每日两次生理盐水鼻窦冲洗,同时10天培养导向口服抗生素。
  • 疗效评估包括微生物学结果、Lund-Kennedy评分、VAS症状评分和SNOT-22。

临床怎么用

  • 对于难治性CRS术后感染患者,16.5% MH+1.3 mg/mL MGO冲洗可作为安全选项,但不应替代培养导向抗生素联合盐水冲洗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Manuka honey (MH) has significant antibiofilm activity in vitro and in vivo against Staphylococcus aureus, methicillin-resistant S aureus (MRSA), and Pseudomonas aeruginosa. This is the first randomized, single-blinded, placebo-controlled phase 1 clinical trial investigating the safety and preliminary efficacy of MH with augmented methylglyoxal (MGO) rinses in recalcitrant chronic rhinosinusitis (CRS). METHODS: Patients were included after previously undergoing endoscopic sinus surgery and presenting with signs and symptoms of sinus infection with positive bacterial cultures on sinus swabs. Patients were randomized to receive 14 days of twice-daily 16.5% MH + 1.3 mg/mL MGO sinonasal rinses and concurrent 10 days of placebo tablets (MH), or 14 days of twice-daily saline sinonasal rinses and concurrent 10 days of culture-directed antibiotic therapy (CON). Safety observations included the University of Pennsylvania Smell Identification Test (UPSIT) and adverse-event (AE) reporting. Efficacy was assessed comparing microbiology results, Lund-Kennedy scores (LKSs), and symptom scores using the visual analog scale (VAS) and 22-item Sino-Nasal Outcome Test (SNOT-22). RESULTS: Twenty-five patients completed the study. MH demonstrated a good safety profile with no major AEs and no changes in UPSIT. Six of 10 (60%) MH patients had a reduction in bacterial culture rate with 1 of 10 of those having negative cultures, compared with 12 of 15 (80%) in the control group with 7 of 15 having negative cultures upon completion of the study. CONCLUSION: This study concludes that twice-daily 16.5% MH augmented with 1.3 mg/mL MGO sinonasal rinses alone for 14 days is safe but not superior to culture-directed oral antibiotics and twice-daily saline rinses.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Ooi ML, Jothin A, Bennett C, et al. Manuka honey sinus irrigations in recalcitrant chronic rhinosinusitis: phase 1 randomized, single-blinded, placebo-controlled trial. Int Forum Allergy Rhinol. 2019. PMID: 31461581. doi:10.1002/alr.22423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。